Breast cancer is the leading cause of death from cancer in women worldwide, and the
second most common cause of death from cancer in women in the United States. Risk …

The management of human epidermal growth factor receptor (HER2)–positive breast cancer
(BC) has rapidly evolved over the last 20 years. Major advances have led to US Food and …

Purpose To provide guidance to clinicians regarding therapy for patients with brain
metastases from solid tumors. Methods ASCO convened an Expert Panel and conducted a …

Importance ERRB2 (formerly HER2)–positive advanced breast cancer (ABC) remains
typically incurable with optimal treatment undefined in later lines of therapy. The chimeric …

Background Despite therapeutic advances in HER2-positive metastatic breast cancer,
resistance to trastuzumab inevitably develops. In the PHOEBE study, we aimed to assess …

PURPOSE To update key recommendations of the American Society of Clinical
Oncology/College of American Pathologists estrogen (ER) and progesterone receptor (PgR) …

PURPOSE To update evidence-based guideline recommendations to practicing oncologists
and others on systemic therapy for patients with human epidermal growth factor receptor 2 …

Background In the primary analysis of the HER2CLIMB trial, tucatinib added to trastuzumab
and capecitabine significantly improved overall survival (OS) and progression-free survival …

Background Patients with human epidermal growth factor receptor 2 (HER2)–positive
metastatic breast cancer who have disease progression after therapy with multiple HER2 …

Purpose.—To update key recommendations of the American Society of Clinical
Oncology/College of American Pathologists estrogen receptor (ER) and progesterone …